Use of Bromhexine and Hydroxychloroquine for Treatment of COVID-19 Pneumonia

Mežnar et al., NCT04355026, NCT04355026, Jul 2020

HCQ for COVID-19

1st treatment shown to reduce risk in March 2020, now with p < 0.0000000001 from 426 studies, used in 59 countries.

No treatment is 100% effective.
Protocols combine treatments.

Estimated 90 patient HCQ late treatment RCT with results not reported over 6 years after estimated completion.
37 HCQ RCTs have results missing long after expected1-37
The trials report a total of 20,499 patients, with 12 trials having actual enrollment of 3,639, and the remainder estimated.
Study covers TMPRSS2 inhibitors, bromhexine, and HCQ.
Mežnar et al., 31 Jul 2020, Randomized Controlled Trial, trial NCT04355026 (history).
Late treatment
is less effective